WASHINGTON — Health Secretary Robert F. Kennedy Jr. was uncharacteristically chummy with pharma executives at the White House on Thursday as he cheered the Trump administration’s plan for lowering obesity medication prices. Kennedy has railed against drugmakers in the past, and his lifestyle-focused “Make America Healthy Again” movement has opposed Medicare coverage of GLP-1 weight loss drugs.

But he struck a different tone in commenting on the p resident’s deal to expand access to the popular drugs made by Eli Lilly and Novo Nordisk, including for Medicare and Medicaid patients, calling it “a momentous accomplishment.”

“This is a tool in the toolkit,” Kennedy said in the Oval Office, with Lilly and Novo’s CEOs standing nearby. “It is not a silver bullet. It is an arrow in our quiver.”

See Full Page